- The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD
- The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions
- 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects
Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies like Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been ongoing, partly charging what has come to be referred to as the psychedelic renaissance.
Research has so far shown that the drugs – ketamine, psilocybin, MDMA (also known as ecstasy), and LSD – could potentially remedy mental conditions such as…
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
